Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company specializing in rare and serious conditions and specialty plasma-derived products, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results announcement for March 5, 2025, before U.S. markets open.
The company will host an investment community conference call at 8:00 AM ET on the same day. Investors can participate through various dial-in numbers: 1-877-413-7208 (U.S.), 1-201-689-8555 (International), or 1-809-406-247 (Israel) using conference ID 13751522. The call will also be available via webcast.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), un'azienda biopharmaceutical globale in fase commerciale specializzata in condizioni rare e gravi e prodotti derivati dal plasma, ha programmato l'annuncio dei risultati finanziari per il quarto trimestre e l'anno fiscale 2024 per il 5 marzo 2025, prima dell'apertura dei mercati statunitensi.
L'azienda ospiterà una conferenza telefonica per la comunità degli investitori alle 8:00 AM ET dello stesso giorno. Gli investitori possono partecipare tramite vari numeri di accesso: 1-877-413-7208 (USA), 1-201-689-8555 (Internazionale) o 1-809-406-247 (Israele) utilizzando l'ID conferenza 13751522. La chiamata sarà disponibile anche tramite webcast.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), una empresa biofarmacéutica global en etapa comercial especializada en condiciones raras y graves y productos derivados del plasma, ha programado el anuncio de sus resultados financieros del cuarto trimestre y año fiscal 2024 para el 5 de marzo de 2025, antes de la apertura de los mercados en EE. UU.
La compañía llevará a cabo una conferencia telefónica para la comunidad inversora a las 8:00 AM ET el mismo día. Los inversores pueden participar a través de varios números de acceso: 1-877-413-7208 (EE. UU.), 1-201-689-8555 (Internacional) o 1-809-406-247 (Israel) utilizando el ID de conferencia 13751522. La llamada también estará disponible a través de webcast.
카마다 (NASDAQ: KMDA; TASE: KMDA.TA)는 희귀 및 중증 질환과 특수 혈장 유래 제품을 전문으로 하는 상업 단계의 글로벌 생명공학 회사로, 2024 회계연도 4분기 재무 결과 발표를 2025년 3월 5일 미국 시장 개장 전에 예정하고 있습니다.
회사는 같은 날 오전 8:00 ET에 투자자 커뮤니티를 위한 전화 회의를 개최할 예정입니다. 투자자들은 다음의 다양한 다이얼인 번호를 통해 참여할 수 있습니다: 1-877-413-7208 (미국), 1-201-689-8555 (국제), 또는 1-809-406-247 (이스라엘)로 회의 ID 13751522를 사용하여 참여할 수 있습니다. 이 통화는 웹캐스트를 통해서도 이용 가능합니다.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), une entreprise biopharmaceutique mondiale en phase commerciale spécialisée dans les maladies rares et graves ainsi que dans les produits dérivés du plasma, a programmé l'annonce de ses résultats financiers pour le quatrième trimestre et l'exercice 2024 pour le 5 mars 2025, avant l'ouverture des marchés américains.
L'entreprise organisera une conférence téléphonique pour la communauté des investisseurs à 8h00 ET le même jour. Les investisseurs peuvent participer via divers numéros d'accès : 1-877-413-7208 (États-Unis), 1-201-689-8555 (International) ou 1-809-406-247 (Israël) en utilisant l'ID de conférence 13751522. L'appel sera également disponible par webcast.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), ein globales biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf seltene und schwerwiegende Erkrankungen sowie spezielle plasmaderivierte Produkte spezialisiert hat, hat die Bekanntgabe seiner finanziellen Ergebnisse für das vierth Quartal und das Geschäftsjahr 2024 für den 5. März 2025 vor der Eröffnung der US-Märkte angesetzt.
Das Unternehmen wird am selben Tag um 8:00 Uhr ET eine Telefonkonferenz für die Investmentgemeinschaft abhalten. Investoren können über verschiedene Einwahlnummern teilnehmen: 1-877-413-7208 (USA), 1-201-689-8555 (International) oder 1-809-406-247 (Israel) unter Verwendung der Konferenz-ID 13751522. Der Anruf wird auch über ein Webcast verfügbar sein.
- None.
- None.
Company to Host Conference Call at 8:00am ET
REHOVOT, Israel, and HOBOKEN, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2024, prior to the open of the U.S. financial markets on Wednesday, March 5, 2025.
Kamada management will host an investment community conference call on Wednesday, March 5 at 8:00am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-413-7208 (from within the U.S.), 1-201-689-8555 (International), or 1-809-406-247 Investors (from Israel) using conference I.D. 13751522. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1706625&tp_key=810bb27504
About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth from its commercial activities, including continued investment in the commercialization and life cycle management of its proprietary products, which include six FDA-approved specialty plasma-derived products: KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom products, and the products in the distribution segment portfolio, mainly through the launch of several biosimilar products in Israel. Second, the Company aims to secure significant new business development, in-licensing, collaboration, and/or merger and acquisition opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term growth. Third, the Company is expanding its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns two operating plasma collection centers in the United States, in Beaumont Texas and Houston Texas, and plans to open the third center in San Antonio, Texas, by the end of the first quarter of 2025. Lastly, the Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need, with the lead product candidate Inhaled AAT, for which the Company is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
FAQ
When will Kamada (KMDA) release its Q4 and FY 2024 earnings?
How can investors join Kamada's (KMDA) Q4 2024 earnings call?
What is the conference ID for Kamada's (KMDA) Q4 2024 earnings call?
Will Kamada's (KMDA) Q4 2024 earnings call be available via webcast?
